Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood samples sought to uncover hidden leukemia markers in seniors

NCT ID NCT07250217

Knowledge-focused Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find specific epigenetic markers in the blood of elderly patients with acute myeloid leukemia (AML). Researchers will analyze DNA from blood samples of 30 AML patients and compare them to samples from healthy older adults undergoing heart surgery. The goal is to better understand the disease, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. / Control Group Inclusion Criteria: * Age ≥ 60 years; * Scheduled for cardiac surgery involving sternotomy; * Normal blood count within the two months preceding sampling; * Affiliated with, or beneficiary of, a social security system; * Written informed consent to participate in the study. Exclusion Criteria: * Patients deemed unsuitable for sampling by the surgeon performing the procedure; * Patients under legal protection measures; * Patients under judicial supervision or deprived of liberty by judicial or administrative decision; * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV). 2. / AML Group Inclusion Criteria: * Age ≥ 60 years; * Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment; * Affiliated with, or beneficiary of, a social security system; * Written informed consent to participate in the study. Exclusion Criteria: * Diagnosis of a hematologic disease other than AML; * Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia; * Previous treatment for AML other than hydroxyurea; * Severe comorbidities that could interfere with the study, as assessed by the principal investigator; * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV); * Patients under legal protection; * Patients under judicial supervision or deprived of liberty by judicial or administrative decision.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloblastic leukemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • GHRMSA

    RECRUITING

    Mulhouse, 68100, France

  • Groupe Hospitalier de la Région de Mulhouse et Sud Alsace

    RECRUITING

    Mulhouse, Alsace, 68100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.